Three percent to 5% of non-small cell lung cancer (NSCLC) patients have a mutation in the ALK gene and may benefit from treatment with critozinib (Xalkori). In 2011, the FDA approved a test that samples NSCLC tissue and highlights ALK mutations with a glowing tag. Now, the FDA has approved an automated scanning system, GenASIs Scan & Analysis, for examining these tagged tissue samples. The automated system, produced by Applied Spectral Imaging, promises fast, reliable detection of ALK mutations in NSCLC.
In revised results from a phase II clinical trial, Peregrine Pharmaceuticals’ experimental cancer drug bavituximab appeared less effective than in previous reports. While patients with advanced non-small cell lung cancer (NSCLC) receiving a higher dose of bavituximab plus chemotherapy as a second-line treatment survived longer than patients receiving chemotherapy alone or with a lower bavituximab dose, the difference was not statistically significant. In September 2012, preliminary results from the same trial had reported that the higher bavituximab dose doubled patients’ survival time. Since then, an internal review revealed problems with drug vial labeling, which distorted initial results.
Radiation therapy is traditionally thought to suppress the immune system. However, it may also stimulate immune cells that can fight against tumor growth. A recent study found that increased levels of the immune cell proteins CD4 and CD8 correlated with improved survival in non-small cell lung cancer (NSCLC) patients who had received radiation therapy after tumor removal. The results suggest that immune cell protein levels could be used to help determine prognosis for patients receiving such “adjuvant therapy.”
Treatment of advanced nonsmall cell lung cancer (NSCLC) has rapidly changed over the last decade. On the basis of the progress made in cancer biology, the old-fashioned ‘one size fits all’ chemotherapeutic approach is shifting to a novel approach in which treatment choice is mainly based on the tumor’s biological genotype. The aim of the present review is to describe the anaplastic lymphoma kinase (ALK) translocation as a prominent molecular driver aberration in NSCLC, its prognostic and predictive role, and the new available treatment options.
Treatments of non-small-cell lung cancer (NSCLC)—particularly of the squamous subtype—are limited. In this article, we describe the immunomodulatory environment in NSCLC and the potential for therapeutic targeting of the immune system through cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) immune-checkpoint pathway blockade.
Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced today that its GenASIs Scan & Analysis automated microscopy platform has received FDA clearance as an aid in ALK gene analysis for lung cancer therapy selection. The introduction of automation in ALK therapy selection represents a new era in personalized medicine for patients with NSCLC (Non-Small-Cell-Lung-Cancer).
GenASIs Scan & Analysis offers clinicians a way to automatically perform genetic analysis on tissue samples, stained with the Abbott ALK™ probe kit, and identify the ALK gene rearrangement.
The tumor microenvironment can polarize innate immune cells to a pro-angiogenic phenotype. Decidual NK cells show an angiogenic phenotype, yet the role for natural killer (NK) innate lymphoid cells in tumor angiogenesis remains to be defined. We investigated NK cells from patients with surgically resected non-small cell lung cancer (NSCLC) and controls. Our data suggest that NK cells in NSCLC act as pro-angiogenic cells, particularly evident for squamous cell carcinoma and in part mediated by TGFβ1.